Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.

Au, L.; Fendler, A.; Shepherd, STC; Rzeniewicz, K.; Cerrone, M.; Byrne, F.; Carlyle, E.; Edmonds, K.; Del Rosario, L.; Shon, J.; Haynes, W.A.; Ward, B.; Shum, B.; Gordon, W.; Gerard, C.L.; Xie, W.; Joharatnam-Hogan, N.; Young, K.; Pickering, L.; Furness, AJS; Larkin, J.; Harvey, R.; Kassiotis, G.; Gandhi, S.; Swanton, C.; Fribbens, C.; Wilkinson, K.A.; Wilkinson, R.J.; Lau, D.K.; Banerjee, S.; Starling, N.; Chau, I.; Turajlic, S.

doi:10.1038/s41591-021-01387-6

Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.

Details

Download: 34040262_BIB_29705A2A49CB.pdf (4332.84 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0

Serval ID

serval:BIB_29705A2A49CB

Type

Article: article from journal or magazin.

Collection

Publications

Institution

Production externe

Title

Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.

Journal

Nature medicine

Author(s)

Au L., Fendler A., Shepherd STC, Rzeniewicz K., Cerrone M., Byrne F., Carlyle E., Edmonds K., Del Rosario L., Shon J., Haynes W.A., Ward B., Shum B., Gordon W., Gerard C.L., Xie W., Joharatnam-Hogan N., Young K., Pickering L., Furness AJS, Larkin J., Harvey R., Kassiotis G., Gandhi S., Swanton C., Fribbens C., Wilkinson K.A., Wilkinson R.J., Lau D.K., Banerjee S., Starling N., Chau I., Turajlic S.

Working group(s)

Crick COVID-19 Consortium, CAPTURE Consortium

Contributor(s)

Kassiotis G., Gandhi S., Swanton C., Au L., Fendler A., Shepherd STC, Byrne F., Shum B., Gerard C., Young K., Pickering L., Furness AJS, Larkin J., Kassiotis G., Wilkinson K.A., Wilkinson R.J., Banerjee S., Starling N., Chau I., Turajlic S.

ISSN

1546-170X (Electronic)

ISSN-L

1078-8956

Publication state

Published

Issued date

08/2021

Peer-reviewed

Oui

Volume

Number

Pages

1362-1366

Language

english

Notes

Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Abstract

Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit-risk profile remains strongly in favor of COVID-19 vaccination in this population.

Keywords

COVID-19/metabolism, COVID-19/prevention & control, COVID-19 Vaccines/adverse effects, Colorectal Neoplasms/metabolism, Cytokine Release Syndrome, Humans, Male, SARS-CoV-2/isolation & purification

DOI

10.1038/s41591-021-01387-6

Pubmed

34040262

Web of science

000654957100001

Open Access

Yes

Create date

04/06/2021 17:35

Last modification date

11/01/2022 14:33